Novo Nordisk completes $4.7 billion acquisition of Akero Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Novo Nordisk has completed its acquisition of Akero Therapeutics
December 9, 2025 8:52 AM ESTBagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 Novo Nordisk and Akero Therapeutics Inc. (Akero) (Nasdaq: AKRO) today announced that Novo Nordisks acquisition of Akero, announced on 9 October 2025, has been completed.
With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right (CVR). Each CVR entitles its holder to an additional payment of 6 USD per share in cash (or aggregated value of 0.5... More
